Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: Systematic review and meta-analyses of randomized controlled trials

Drugs

Volumn 73, Issue 11, 2013, Pages 1171-1182

  Sardar, Partha ^a   Chatterjee, Saurav ^b   Mukherjee, Debabrata ^c  

^a METROPOLITAN HOSPITAL CENTER   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; PLACEBO; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; MORTALITY; NUMBERS NEEDED TO TREAT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VENOUS THROMBOEMBOLISM; ORAL DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84880769850     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0082-7     Document Type: Review

References (19)

1. Schafer AI. Venous thrombosis as a chronic disease. N Engl J Med. 1999;340:955-6.
2. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
3. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients. Haematologica. 2007;92:199-205.
4. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis. 2008;25:37-44.
5. Osinbowale O, Ali L, Chi YW. Venous thromboembolism: a clinical review. Postgrad Med. 2010;122:54-65.
6. Connors JM. Extended treatment of venous thromboembolism. N Engl J Med. 2013;368:767-9.
7. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-34.
8. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-9.
9. Agnelli G, Buller HR, Cohen A, AMPLIFY-EXT Investigators, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368:699-708.
10. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363:2499-510.
11. Schulman S, Kearon C, Kakkar AK, RE-MEDY Trial Investigators; RE-SONATE Trial Investigators, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709-18.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;18(151):W65-94.
13. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, Version 5.1.0 (updated March 2011). Available at: http://www.cochrane-handbook.org.
14. Fox BD, Kahn SR, Langleben D, et al. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ. 2012;345:e7498.
15. Becattini C, Agnelli G, Schenone A, WARFASA Investigators, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959-67.
16. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-7.
17. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:Suppl:454S-545S (Erratum, Chest 2008;134:892).
18. Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in 'real world' patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013. doi: 10.1016/j.jacc.2013.03.020.
19. Sharma A, Chatterjee S, Lichstein E, et al. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost. 2012;10:2053-60.